Enanta Pharmaceuticals Inc (ENTA)

[DewDiligence]

ABBV 4Q25 Mavyret sales=$324M, +9% YoY in constant_currency:

https://www.prnewswire.com/news-releases/abbvie-reports-full-year-and-fourth-quarter-2025-financial-results-302678316.html

The geographic breakdown is: +18% YoY in the US; +1% YoY ex-US (in constant currency). Clearly, Mavyret’s expanded FDA label is driving growth in the US (#msg-176309105).